Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC
First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.
Source: medscape.com
Msi H News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Msi H. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Msi H Today - Breaking & Trending Today
FDA OKs Dostarlimab Plus Chemo for Endometrial Cancer
The approval moves dostarlimab's endometrial cancer indication earlier in the treatment paradigm.
Source: medscape.com
FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer
The FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of dostarlimab plus chemotherapy for use in adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.
Source: onclive.com
EMA Validates Type II Variation Application for Dostarlimab/Chemo for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
The European Medicines Agency has validated a type II variation for potential approval of dostarlimab in combination with carboplatin and paclitaxel for the treatment of patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.
Source: onclive.com
'Home Run': Immunotherapy Add-on for Advanced Endometrial Cancer
Two new studies show that adding immunotherapy with pembrolizumab or dostarlimab to chemotherapy significantly boosts progression-free survival in patients with advanced endometrial cancer.
Source: medscape.com